Hantz Financial Services
NTLA icon

Hantz Financial Services’s Intellia Therapeutics NTLA Stock Holding History

Hantz Financial Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7K Hold
586
– – ﹤0.01% 2161
2026
Q2 		$10K Sell
586
-210
-26% -$2.94K ﹤0.01% 2084
2026
Q1 		$10K Buy
+796
New +$10.1K ﹤0.01% 2043

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Contrarius Group Holdings
Contrarius Group Holdings Hamilton, Bermuda $2.05B AUM 66.09% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Hantz Financial Services's NTLA Position: Q3 2026 in Review

Hantz Financial Services held its Intellia Therapeutics (NTLA) position steady in Q3 2026 at 586 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #2161.

Hantz Financial Services first reported a position in NTLA in Q1 2026 and has held it in 3 quarters since. The position peaked at $10K in Q2 2026. 156 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Hantz Financial Services held 586 shares of Intellia Therapeutics worth $7K as of Q3 2026.
  • Hantz Financial Services left its Intellia Therapeutics share count unchanged in Q3 2026.
  • Intellia Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q3 2026, its #2161 holding.
  • Hantz Financial Services first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Hantz Financial Services's Intellia Therapeutics position peaked at $10K in Q2 2026.
  • 156 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Hantz Financial Services's 13F filing for Q3 2026, filed 9 Nov 2026.